by Playfuls Staff |
25th March 2007
For parents, 8 million cases of acute middle ear infections
every year add up to a lot of sleepless nights and trips to the pediatrician.
But new research from a collaboration between
Rockefeller
University and
St.
[more] Jude Children’s Hospital could change all that.
In the March 23 issue of PLoS Pathogens, Rockefeller’s
Vincent A. Fischetti and colleagues at St. Jude show that middle ear infections
in mice can be prevented by giving the mice a lysin – a protein derived from a
virus that infects bacteria. The new technology may prevent children with the
flu from developing secondary ear infections and would be an attractive
alternative to traditional antibiotics, to which bacteria are rapidly becoming
resistant.
The bacteria that cause middle ear infections, Streptococcus
pneumoniae, aren’t transmitted at school. They already reside on the mucosal
membranes in the nose, waiting for their chance to strike. When a child catches
the flu, or another virus that causes an upper respiratory infection, the
bacteria seize the opportunity and migrate to the middle ear, causing a
secondary infection. The new treatment would kill the bacteria before it had a
chance to move.
"These bacteria take advantage of a viral infection by
striking when our resistance is lowered," says Fischetti, head of
Rockefeller’s Laboratory of Bacterial Pathogenesis and Immunology. "You
should start taking an antibiotic the moment you come down with the viral
infection to prevent the secondary infection, but physicians are reluctant to
do this for fear of increasing resistance to antibiotics. So we’re really in a
catch-22 situation."
Fischetti’s lab has done extensive research on lysins, which
are proteins derived from viruses that normally infect bacteria. After a virus
has infected the bacteria and replicated, it uses lysins to punch holes in the
bacteria’s cell wall, killing the bacteria, in order to escape. Fischetti’s lab
has studied many different lysins and found that they work even from outside
the bacterial cell as well as from the inside. In addition, unlike antibiotics,
which kill many of the body’s beneficial bacteria along with the
disease-causing ones they target, lysins are highly specific. Each lysin will
only kill a specific type of bacteria, leaving the body’s normal flora untouched.
"We knew from our previous experiments that if you
treat an animal infected or colonized with pneumococci or streptococci with
these lysins, you could cure or decolonize them," says Fischetti.
"But I was looking for a way to see if lysins would work for secondary
infections too, and John McCullers had a very nice model system."
The two researchers collaborated – Fischetti sent McCullers,
a physician at St. Jude Children’s Hospital Department of Infectious Diseases,
the lysin, and McCullers tested his mice. He colonized his mice with S.
pneumoniae, treated some of them with the lysin and then gave them all
influenza. Eighty percent of the mice that did not receive the lysin came down
with middle ear infections, but none of the mice given the lysin did. The
treatment was 100 percent effective. "It is really a no-brainer
experiment," says Fischetti. "If the bacteria aren’t there, they
cannot cause the secondary infection."
"Secondary bacterial infections cause much of the
sickness and about 25 percent of all deaths during flu season," says
McCullers. "Eliminating these secondary infections could dramatically
reduce sickness and death rates."